Mamta Parikh, M.D., M.S. for UC Davis Health

Mamta Parikh, M.D., M.S.

Assistant Professor, Division of Hematology and Oncology

To see if Mamta Parikh is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).





Internal Medicine

Locations and Contact

UC Davis Comprehensive Cancer Center

Hematology/Oncology Clinic
4501 X Street
Sacramento, CA 95817

Get Directions

Phone: 916-734-5959

Additional Numbers



Physician Referrals

800-4-UCDAVIS (800-482-3284)

Philosophy of Care

Dr. Parikh believes that every cancer patient deserves a compassionate and clear explanation of their diagnosis as well as their treatment options. She believes in the importance of clinical research, which has resulted in new, more effective therapies for the treatment of genitourinary malignancies, and offers hope for the future of how these cancers are treated. She strives to provide the best possible care for patients, providing the latest advances in therapy, offering participation in clinical trials which have the potential to further scientific advances and improving outcomes, and involving other specialists so that patients receive the best multidisciplinary treatment.

Clinical Interests

Dr. Parikh is a medical oncologist specializing in the treatment of genitourinary malignancies, including bladder cancer, kidney cancer, prostate cancer, and testicular cancer.

Research/Academic Interests

Dr. Parikh's research focuses on improving outcomes in bladder, kidney, and prostate cancer, by investigating new agents in clinical trials in patients with these malignancies, and also by lookng at cancer outcomes in California. She has particular clinical research interests in improving the effect of immunotherapy in bladder cancer.


Hematology and Oncology

Center/Program Affiliation

UC Davis Comprehensive Cancer Center

Undergraduate School

B.S., Chemistry, Boston University, Boston MA 1995

Medical School

M.D., UC Davis School of Medicine, Davis CA 2011

Other School

M.S., Organic Chemistry, UC Irvine, Irvine CA 1997


Internal Medicine, UC Davis Medical Center, Sacramento CA 2011-2012


Internal Medicine, UC Davis Medical Center, Sacramento CA 2012-2014


Hematology/Oncology, UC Davis Medical Center, Sacramento CA 2014-2017

K12 Paul Calabresi Career Development for Clinical Oncology, National Cancer Institute, 2018

Joseph Sullivan Research Award, UC Davis Comprehensive Cancer Center, 2016

Allan T. Nunn Memorial Scholarship, UC Davis School of Medicine, 2011

American Institute of Chemists Award, American Chemical Society, 1995

Wang G, Nardo L, Parikh M, Abdelhafez YG, Li E, Spencer BA, Qi J, Jones T, Cherry SR, Badawi RD. Total-Body PET Multiparametric Imaging of Cancer Using a Voxel-wise Strategy of Compartmental Modeling. J Nucl Med. 2021 Nov 18:jnumed.121.262668. doi:10.2967/jnumed.121.262668. Epub ahead of print. PMID:34795014.

Parikh M. Routine Bone Imaging for Metastatic Renal Cell Carcinoma: Is it Time? J Kidney Cancer VHL. 2021 Oct 14;8(4):20-21. doi:10.15586/jkcvhl.v8i4.207. PMID:34722127.

Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, Lyou Y, Weng P, Parikh R, Teply B, Dreicer R, Emamekhoo H, Michaelson D, Hoimes C, Zhang T, Srinivas S, Kim WY, Cui Y, Newman E, Lara PN Jr. Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 Oct 1;7(10):1536-1543. doi:10.1001/jamaoncol.2021.3441. PMID:34436521.

Parikh M, Powles T. Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. Am Soc Clin Oncol Educ Book. 2021 Jun;41:e182-e189. doi:10.1200/EDBK_323835. PMID:34061558.

Parikh M, Liu C, Wu CY, Evans CP, Dall'Era M, Robles D, Lara PN, Agarwal N, Gao AC, Pan CX. Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Sci Rep. 2021 Mar 18;11(1):6377. doi:10.1038/s41598-021-85969-x. PMID:33737681.

Parikh M, Bajwa P. Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. Semin Nephrol. 2020 Jan;40(1):76-85. doi:10.1016/j.semnephrol.2019.12.009. PMID:32130969.

Parikh M, Pan CX, Beckett LA, Li Y, Robles DA, Aujla PK, Lara PN Jr. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study. Clin Genitourin Cancer. 2018 Dec;16(6):421-428.e1. doi:10.1016/j.clgc.2018.07.004. Epub 2018 Jul 12. PMID:30166228.

Parikh M, Galkin M, Brunson A, Keegan T, Chew HK. Breast cancer-specific survival in patients with HER2-positive, node-negative T1a and T1b breast cancer. Cancer Treat Res Commun. 2018;16:38-44. doi:10.1016/j.ctarc.2018.06.001. Epub 2018 Jun 13. PMID:31299001.

Parikh M, Lara PN Jr. Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type. Annu Rev Med. 2018 Jan 29;69:209-221. doi:10.1146/annurev-med-041916-124132. Epub 2017 Nov 16. PMID:29144835.

Lara PN Jr, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. JCO Precis Oncol. 2017;2017:PO.17.00065. doi:10.1200/PO.17.00065. Epub 2017 Nov 2. PMID:29629426.